Kraig Biocraft Labs Files 8-K with Material Agreements

Ticker: KBLB · Form: 8-K · Filed: Jan 21, 2025 · CIK: 1413119

Kraig Biocraft Laboratories, Inc 8-K Filing Summary
FieldDetail
CompanyKraig Biocraft Laboratories, Inc (KBLB)
Form Type8-K
Filed DateJan 21, 2025
Risk Levelmedium
Pages5
Reading Time6 min
Key Dollar Amounts$10 million, $25,000, $10,000, $15,000
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, equity-sale, regulation-fd

Related Tickers: KBLG

TL;DR

KRAIG BIOCRAFT LABS (KBLG) filed an 8-K on Jan 21, 2025, reporting material agreements and equity sales.

AI Summary

On January 21, 2025, Kraig Biocraft Laboratories, Inc. filed an 8-K report detailing several key events. The company entered into a material definitive agreement, engaged in unregistered sales of equity securities, and provided a Regulation FD disclosure. The filing also included financial statements and exhibits.

Why It Matters

This 8-K filing indicates significant corporate actions, including new agreements and equity transactions, which could impact the company's financial structure and future operations.

Risk Assessment

Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and operational risks.

Key Players & Entities

  • Kraig Biocraft Laboratories, Inc. (company) — Registrant
  • January 21, 2025 (date) — Date of earliest event reported

FAQ

What type of material definitive agreement did Kraig Biocraft Laboratories, Inc. enter into?

The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on or before January 21, 2025.

What was the purpose of the unregistered sales of equity securities?

The filing does not disclose the specific purpose or terms of the unregistered sales of equity securities.

What information is contained within the Regulation FD disclosure?

The filing indicates a Regulation FD disclosure was made, but the specific content of this disclosure is not detailed in the provided text.

What financial statements and exhibits are included in this filing?

The filing states that financial statements and exhibits are included, but their specific content is not detailed in the provided text.

When was Kraig Biocraft Laboratories, Inc. incorporated and in which state?

Kraig Biocraft Laboratories, Inc. was incorporated in Wyoming.

Filing Stats: 1,413 words · 6 min read · ~5 pages · Grade level 13.3 · Accepted 2025-01-21 17:14:03

Key Financial Figures

  • $10 million — the right to sell to the Investor up to $10 million of its shares of common stock, subject
  • $25,000 — estor a structuring fee in an amount of $25,000, of which $10,000 has been paid, and $1
  • $10,000 — g fee in an amount of $25,000, of which $10,000 has been paid, and $15,000 shall be pai
  • $15,000 — 00, of which $10,000 has been paid, and $15,000 shall be paid on the earlier of (a) the

Filing Documents

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 10.1 Standby Equity Purchase Agreement dated as of January 21, 2025, by and between the Company and YA II PN, LTD. 99.1 Press Release, dated January 21, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 21, 2025 KRAIG BIOCRAFT LABORATORIES, INC. By: /s/ Kim Thompson Kim Thompson Chief Executive Officer, Chief Financial Officer and Director

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.